In addition, there is an ongoing clinical trial (the SAXAPCOS trial NCT03480022) investigating the effect of liraglutide (another GLP-1 RA) for treatment of patients with PCOS and obesity. This evidence concerns the gene GLP1R and polycystic ovary syndrome.